233 related articles for article (PubMed ID: 22113087)
1. Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence.
D'Souza DC; Singh N; Elander J; Carbuto M; Pittman B; Udo de Haes J; Sjogren M; Peeters P; Ranganathan M; Schipper J
Neuropsychopharmacology; 2012 Mar; 37(4):1036-46. PubMed ID: 22113087
[TBL] [Abstract][Full Text] [Related]
2. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Krystal JH; Karper LP; Seibyl JP; Freeman GK; Delaney R; Bremner JD; Heninger GR; Bowers MB; Charney DS
Arch Gen Psychiatry; 1994 Mar; 51(3):199-214. PubMed ID: 8122957
[TBL] [Abstract][Full Text] [Related]
3. Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects.
D'Souza DC; Carson RE; Driesen N; Johannesen J; Ranganathan M; Krystal JH;
Biol Psychiatry; 2018 Sep; 84(6):413-421. PubMed ID: 29499855
[TBL] [Abstract][Full Text] [Related]
4. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study.
Deakin JF; Lees J; McKie S; Hallak JE; Williams SR; Dursun SM
Arch Gen Psychiatry; 2008 Feb; 65(2):154-64. PubMed ID: 18250253
[TBL] [Abstract][Full Text] [Related]
5. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial.
Schoemaker JH; Jansen WT; Schipper J; Szegedi A
J Clin Psychopharmacol; 2014 Apr; 34(2):190-8. PubMed ID: 24525661
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological modelling of dissociation and psychosis: an evaluation of the Clinician Administered Dissociative States Scale and Psychotomimetic States Inventory during nitrous oxide ('laughing gas')-induced anomalous states.
Piazza GG; Iskandar G; Hennessy V; Zhao H; Walsh K; McDonnell J; Terhune DB; Das RK; Kamboj SK
Psychopharmacology (Berl); 2022 Jul; 239(7):2317-2329. PubMed ID: 35348804
[TBL] [Abstract][Full Text] [Related]
7. Perceptual distortions and delusional thinking following ketamine administration are related to increased pharmacological MRI signal changes in the parietal lobe.
Stone J; Kotoula V; Dietrich C; De Simoni S; Krystal JH; Mehta MA
J Psychopharmacol; 2015 Sep; 29(9):1025-8. PubMed ID: 26152321
[TBL] [Abstract][Full Text] [Related]
8. Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1).
Chue P
Curr Pharm Des; 2013; 19(7):1311-20. PubMed ID: 23194655
[TBL] [Abstract][Full Text] [Related]
9. Low dose ketamine increases prepulse inhibition in healthy men.
Abel KM; Allin MP; Hemsley DR; Geyer MA
Neuropharmacology; 2003 May; 44(6):729-37. PubMed ID: 12681371
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.
Anand A; Charney DS; Oren DA; Berman RM; Hu XS; Cappiello A; Krystal JH
Arch Gen Psychiatry; 2000 Mar; 57(3):270-6. PubMed ID: 10711913
[TBL] [Abstract][Full Text] [Related]
11. Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia: A Systematic Review and Meta-analysis.
Beck K; Hindley G; Borgan F; Ginestet C; McCutcheon R; Brugger S; Driesen N; Ranganathan M; D'Souza DC; Taylor M; Krystal JH; Howes OD
JAMA Netw Open; 2020 May; 3(5):e204693. PubMed ID: 32437573
[TBL] [Abstract][Full Text] [Related]
12. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
[TBL] [Abstract][Full Text] [Related]
13. Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia.
D'Souza DC; Ahn K; Bhakta S; Elander J; Singh N; Nadim H; Jatlow P; Suckow RF; Pittman B; Ranganathan M
Biol Psychiatry; 2012 Nov; 72(9):785-94. PubMed ID: 22717030
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?
Singer P; Dubroqua S; Yee BK
Curr Pharm Des; 2015; 21(26):3771-87. PubMed ID: 26205290
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism.
Krystal JH; Madonick S; Perry E; Gueorguieva R; Brush L; Wray Y; Belger A; D'Souza DC
Neuropsychopharmacology; 2006 Aug; 31(8):1793-800. PubMed ID: 16395307
[TBL] [Abstract][Full Text] [Related]
16. [Effects of a subanaesthetic dose of ketamine on emotional and behavioral state in healthy subjects].
Micallef J; Tardieu S; Gentile S; Fakra E; Jouve E; Sambuc R; Blin O
Neurophysiol Clin; 2003 Jun; 33(3):138-47. PubMed ID: 12909392
[TBL] [Abstract][Full Text] [Related]
17. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function.
Krystal JH; Perry EB; Gueorguieva R; Belger A; Madonick SH; Abi-Dargham A; Cooper TB; Macdougall L; Abi-Saab W; D'Souza DC
Arch Gen Psychiatry; 2005 Sep; 62(9):985-94. PubMed ID: 16143730
[TBL] [Abstract][Full Text] [Related]
18. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans.
Krystal JH; Karper LP; Bennett A; D'Souza DC; Abi-Dargham A; Morrissey K; Abi-Saab D; Bremner JD; Bowers MB; Suckow RF; Stetson P; Heninger GR; Charney DS
Psychopharmacology (Berl); 1998 Feb; 135(3):213-29. PubMed ID: 9498724
[TBL] [Abstract][Full Text] [Related]
19. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
Krystal JH; Abi-Saab W; Perry E; D'Souza DC; Liu N; Gueorguieva R; McDougall L; Hunsberger T; Belger A; Levine L; Breier A
Psychopharmacology (Berl); 2005 Apr; 179(1):303-9. PubMed ID: 15309376
[TBL] [Abstract][Full Text] [Related]
20. Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: linking cognition, brain activity, and psychosis.
Corlett PR; Honey GD; Aitken MR; Dickinson A; Shanks DR; Absalom AR; Lee M; Pomarol-Clotet E; Murray GK; McKenna PJ; Robbins TW; Bullmore ET; Fletcher PC
Arch Gen Psychiatry; 2006 Jun; 63(6):611-21. PubMed ID: 16754834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
